Manufacturing Process Development for Belzutifan, Part 6: Ensuring Scalability for a Deoxyfluorination Reaction-Reference-Cited by-同舟云学术

Manufacturing Process Development for Belzutifan, Part 6: Ensuring Scalability for a Deoxyfluorination Reaction

Published:2021-11-12 Issue: Volume: Page:
ISSN:1083-6160
Container-title:Organic Process Research & Development
language:en
Short-container-title:Org. Process Res. Dev.

Author:

Pirnot Michael¹^ORCID,Stone Kevin¹,Wright Timothy J.¹,Lamberto David J.¹^ORCID,Schoell Jochen²^ORCID,Lam Yu-hong³^ORCID,Zawatzky Kerstin¹,Wang Xiao¹^ORCID,Dalby Stephen M.¹,Fine Adam J.¹^ORCID,McMullen Jonathan P.¹^ORCID

Affiliation:

1. Process Research and Development, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States

2. Process Research and Development, MSD Werthenstein BioPharma, Industrie Nord 1, CH-6105 Schachen, Switzerland

3. Computational and Structural Chemistry, Merck & Co., Inc., Kenilworth, New Jersey 07033, United States

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Physical and Theoretical Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.oprd.1c00239

Reference35 articles.

1. 3-[(1S,2S,3R)-2,3-Difluoro-1-hydroxy-7-methylsulfonylindan-4-yl]oxy-5-fluorobenzonitrile (PT2977), a Hypoxia-Inducible Factor 2α (HIF-2α) Inhibitor for the Treatment of Clear Cell Renal Cell Carcinoma

2. FDA Approves Merck’s Hypoxia-Inducible Factor-2 Alpha (HIF-2α) Inhibitor WELIREGTM (belzutifan) for the Treatment of Patients with Certain Types of Von Hippel–Lindau (VHL) Disease-Associated Tumors. Merck, August 13, 2021. https://www.merck.com/news/fda-approves-mercks-hypoxia-inducible-factor-2-alpha-hif-2%CE%B1-inhibitor-welireg-belzutifan-for-the-treatment-of-patients-with-certain-types-of-von-hippel-lindau-vhl-disease/ (accessed 2021-08-24).

3. The Nobel Prize in Physiology or Medicine 2019. Nobel Media AB, 2020. https://www.nobelprize.org/prizes/medicine/2019/summary/ (accessed 2020-10-22).

4. Manufacturing Process Development for Belzutifan, Part 1: A Concise Synthesis of the Indanone Starting Material

5. Manufacturing Process Development for Belzutifan, Part 2: A Continuous Flow Visible-Light-Induced Benzylic Bromination

Cited by 20 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Enantio- and Diastereoselective Total Synthesis of Belzutifan Enabled by Rh-Catalyzed Hydrogenation;Organic Letters;2024-05-06

2. Evolution of a Green and Sustainable Manufacturing Process for Belzutifan: Part 5─Chemoenzymatic Diastereoselective Fluorination/DKR;Organic Process Research & Development;2024-02-07

3. Evolution of a Green and Sustainable Manufacturing Process for Belzutifan: Part 1─Process History and Development Strategy;Organic Process Research & Development;2024-02-05

4. Evolution of a Green and Sustainable Manufacturing Process for Belzutifan: Part 6─Development of a Nucleophilic Aromatic Substitution in Water;Organic Process Research & Development;2024-02-05

5. Evolution of a Green and Sustainable Manufacturing Process for Belzutifan: Part 3─Development of a Scalable Enzymatic Oxidation Process;Organic Process Research & Development;2024-02-01